Status:
COMPLETED
Atrial Fibrillation Feasibility Certoparin Trial - AFFECT
Lead Sponsor:
Novartis
Conditions:
Persistent Nonvalvular Atrial Fibrillation
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This trial is designed to provide data about feasibility and safety of short-term treatment with the low-molecular-weight heparin certoparin in patients with persistent nonvalvular atrial fibrillation
Eligibility Criteria
Inclusion
- persistent AF (electrical cardioversion is planned)
- written informed consent
Exclusion
- acute clinical signs of venous thromboembolism
- current oral anticoagulation
- indication for medical cardioversion
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00171769
Start Date
April 1 2005
Last Update
February 23 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
East Hanover, New Jersey, United States, 07936
2
Investigative Centers, Germany